KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cells

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4593-4602

  Phatak, Pornima ^a   Dai, Fangping ^b   Butler, Melody ^a   Nandakumar, M P ^a   Gutierrez, Peter L ^a   Edelman, Martin J ^a   Hendriks, Hans ^c   Burger, Angelika M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Hendriks Pharmaceutical Consulting   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H2AX; KML 001; METAARSENITE SODIUM; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ARSENITE SODIUM; ARSENOUS ACID DERIVATIVE; SODIUM DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DNA DAMAGE; DRUG BINDING; DRUG MECHANISM; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CANCER; TELOMERE; BREAST TUMOR; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; LUNG TUMOR; MALE; MASS SPECTROMETRY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ARSENITES; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM COMPOUNDS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TELOMERASE; TELOMERE;

EID: 51649105500     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4572     Document Type: Article

References (39)

1. Miller WH, Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002;62:3893-903.
2. Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998;339: 1341-8.
3. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
4. Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev 2007;33:542-64.
5. Chou WC, Dang CV. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to therapies. Curr Opin Hematol 2005;12:1-6.
6. Zhang TC, Schmitt MT, Mumford JL Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis 2003;24: 1811-7.
7. Rust DM, Soignet SL. Risk/benefit profile of arsenic trioxide. Oncologist 2001;6 Suppl 2:29-32
8. Zhang TC, Cao EH, Li JF, Ma W, Qin JF. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 1999;35:1258-63.
9. Chou WC, Hawkins AL, Barrett JF, Griffin CA, Dang CV. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Invest 2001;108:1541-7.
10. Yih LH, Tseng YY, Wu YC, Lee TC. Induction of centrasome amplification during arsenite-induced mitotic arrest in CGL-2 cells. Cancer Res 2006:66:2098-106.
11. Mei N, Kunugita N, Hirano T, Kasai H. Acute arseniteinduced 8-hydroxyguanine is associated with inhibition of repair activity in cultured human cells. BBRC 2002:297:924-30.
12. Poonepalli A, Balakrishnan L, Khaw AK, et al. Lack of poly(ADP-ribose) polymerase-1 gene product enhances cellular sensitivity to arsenite. Cancer Res 2005:65:10977-83.
13. Wei YM, Ou YX, Bai H, Lu JH, Zhang RL. Down regulation of four arsenic antagonists on apoptosis and telomerase activity induced by arsenic trioxide in three myelocytic leukemia cell lines. Acta Pharmacol Sin 2001;8:725-30.
14. 3 in MGC-803 cells. Eur J Pharmacol 2005:517:1-9.
15. Liu L, Trimarchi JR, Navarro P, Blasco MA, Keefe DL. Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability and apoptosis. J Biol Chem 2003;278:31998-2004.
16. Hendriks H, Dai F, Rademaker B, Yang YJ, Lee SB, Burger AM. The novel compound KML001 induces telomere attrition, senescence and chromosomal instability in tumor cell lines with short telomeres. Eur J Cancer 2004:40 Suppl 2:130.
17. Glienke W, Chow KU, Bauer N, Bergmann L. Downregulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma 2006:47:1629-38.
18. Cookson JC, Dai F, Smith V, et al. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6.8,13-trimethyl-8H- quino[4,3,2- K/] acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol Pharmacol 2005;68:1551-8.
19. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
20. Burger AM. Standard TRAP assay. In: Double JA, Thompson MJ, editors. Telomeres and telomerase: methods in molecular biology. Totowa: The Humana Press: 2002. p. 109-24.
21. Phatak P, Cookson JC, Dai F, et al. Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer 2007:96:1223-33.
22. Ishibashi T, Lippard SJ. Telomere loss in cells treated with cisplatin. Proc Natl Acad Sci U S A 1998;95: 4219-23.
23. dAdda di Fagagna F, Hande MP, Tong WM, et al. Effects of DNA nonhomologous end-joining factors on telomere length and chromosomal stability in mammalian cells Curr Biol 2001;11:1192-6.
24. IJpma AS, Greider CW Short telomeres induce a DNA damage response in Saccharomyces cerevisiae. Mol Biol Cell 2003;14:987-1001.
25. Villanueva JM, Jia X, Yohannes PG, Doetsch PW, Marzilli LG. Cisplatin (cis-Pt(NH(3))(2)CI(2)) and cis-[Pt(NH(3))(2)(H(2)0)(2)](2+) intrastrand cross-linking reactions at the telomere GGGT DNA sequence embedded in a duplex, a hairpin, and a bulged duplex: use of Mg(2+) and Zn(2+) to convert a hairpin to a bulged duplex. Inorg Chem 1999;38:60-80.
26. 3 with DNA and RNA. DNA Cell Biol 2005;24:634-40.
27. Blackburn EH. Telomere states and cell fates. Nature 2000;408:53-6.
28. dAdda di Fagagna F, Reaper PM, Clay-Farrace L, et al. DNA damage checkpoint response in telomereinitiated senescence. Nature 2003;426:194-8.
29. Zhu J, Chen Z, Lallemand-Breitenbach V, de Thé H How acute promyelocytic leukaemia revived arsenic Nat Rev Cancer 2002;2:705-13
30. Phatak P, Burger AM. Telomerase and its potential for therapeutic intervention. Br J Pharmacol 2007: 152:1003-11.
31. Kelland L. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin Cancer Res 2007;13:4960-3.
32. London̄o-Vallejo JA, Der-Sarkissian H, Cazes L. Bacchetti S, Reddel RR. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange Cancer Res 2004;64:2324-7
33. Oikawa S Sequence-specific DNA damage by reactive oxygen species: implications for carcinogenesis and aging. Environ Health Prev Med 2005. 10:65-71.
34. Burger AM. Dai F, Schultes CM, et al. The G-quadruplex interactive molecule BRAC019 inhibits tumor growth, consistent with telomere binding and interference with telomerase function. Cancer Res 2005;65: 1489-96.
35. s3-induced PML or PML/retinoic acid receptor α degradation. J Exp Med 2001;193:1361-71.
36. Yeager TR, Neumann AA, Englezou A. Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999;59 4175-9.
37. Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. Int J Cancer 2006; 119:2255-60.
38. Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, Griffith JK. Association between cancer-free survival and telomere DNA content in prostate tumors J Urol 2005;173:610-4.
39. Griffith JK, Bryant JE, Fordyce CA. Gilliland FD. Joste NE, Moyzis RK. Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma. Breast Cancer Res Treat 1999;54:59-64.